SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Core Insights - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% after the FDA identified deficiencies in its New Drug Application for Anaphylm, an experimental treatment for severe allergic reactions [5] Company Overview - Aquestive Therapeutics is a biopharmaceutical company focused on developing innovative treatments for patients with severe allergic reactions [5] Regulatory Concerns - The FDA's identification of deficiencies in the NDA for Anaphylm has raised concerns regarding the application's approvability ahead of the January 31, 2026, PDUFA action date [5]